Benzquinamide

DB00767

small molecule withdrawn

Deskripsi

Benzquinamide is a discontinued antiemetic compound with antihistaminic, mild anticholinergic, and sedative properties. The mechanism of action is not known, but presumably benzquinamide works via antagonism of muscarinic acetycholine receptors and histamine H1 receptors.

Struktur Molekul 2D

Berat 404.4999
Wujud solid

Peta Jejaring Molekuler
Legenda: ObatTargetGenEnzim(Panah → menunjukkan arah efek / relasi)TransporterCarrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) 1-1.6 hours (for all formulations)
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Incomplete, with 33–39% bioavailability via the capsule and suppository routes, relative to the intramuscular route.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

523 Data
Aclidinium The risk or severity of adverse effects can be increased when Benzquinamide is combined with Aclidinium.
Mianserin Mianserin may increase the anticholinergic activities of Benzquinamide.
Mirabegron The risk or severity of urinary retention can be increased when Benzquinamide is combined with Mirabegron.
Potassium chloride The risk or severity of gastrointestinal ulceration can be increased when Benzquinamide is combined with Potassium chloride.
Pramlintide The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Benzquinamide.
Secretin porcine The therapeutic efficacy of Secretin porcine can be decreased when used in combination with Benzquinamide.
Tiotropium The risk or severity of adverse effects can be increased when Benzquinamide is combined with Tiotropium.
Topiramate The risk or severity of hyperthermia and oligohydrosis can be increased when Benzquinamide is combined with Topiramate.
Umeclidinium The risk or severity of adverse effects can be increased when Benzquinamide is combined with Umeclidinium.
Benzylpenicilloyl polylysine Benzquinamide may decrease effectiveness of Benzylpenicilloyl polylysine as a diagnostic agent.
Betahistine The therapeutic efficacy of Betahistine can be decreased when used in combination with Benzquinamide.
Hyaluronidase (ovine) The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Benzquinamide.
Hyaluronidase (human recombinant) The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Benzquinamide.
Hyaluronidase The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Benzquinamide.
Glycopyrronium The risk or severity of adverse effects can be increased when Benzquinamide is combined with Glycopyrronium.
Botulinum toxin type A The risk or severity of adverse effects can be increased when Benzquinamide is combined with Botulinum toxin type A.
Glucagon Benzquinamide may increase the gastrointestinal motility reducing activities of Glucagon.
Sulpiride Benzquinamide may increase the anticholinergic activities of Sulpiride.
Botulinum toxin type B The risk or severity of adverse effects can be increased when Benzquinamide is combined with Botulinum toxin type B.
Eluxadoline The risk or severity of constipation can be increased when Benzquinamide is combined with Eluxadoline.
Ramosetron The risk or severity of constipation can be increased when Benzquinamide is combined with Ramosetron.
Amphetamine Amphetamine may decrease the sedative activities of Benzquinamide.
Phentermine Phentermine may decrease the sedative activities of Benzquinamide.
Pseudoephedrine Pseudoephedrine may decrease the sedative activities of Benzquinamide.
Benzphetamine Benzphetamine may decrease the sedative activities of Benzquinamide.
Diethylpropion Diethylpropion may decrease the sedative activities of Benzquinamide.
Lisdexamfetamine Lisdexamfetamine may decrease the sedative activities of Benzquinamide.
Mephentermine Mephentermine may decrease the sedative activities of Benzquinamide.
MMDA MMDA may decrease the sedative activities of Benzquinamide.
Midomafetamine Midomafetamine may decrease the sedative activities of Benzquinamide.
2,5-Dimethoxy-4-ethylamphetamine 2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Benzquinamide.
4-Bromo-2,5-dimethoxyamphetamine 4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Benzquinamide.
Tenamfetamine Tenamfetamine may decrease the sedative activities of Benzquinamide.
Chlorphentermine Chlorphentermine may decrease the sedative activities of Benzquinamide.
Methylenedioxyethamphetamine Methylenedioxyethamphetamine may decrease the sedative activities of Benzquinamide.
Dextroamphetamine Dextroamphetamine may decrease the sedative activities of Benzquinamide.
Metamfetamine Metamfetamine may decrease the sedative activities of Benzquinamide.
Iofetamine I-123 Iofetamine I-123 may decrease the sedative activities of Benzquinamide.
Ritobegron Ritobegron may decrease the sedative activities of Benzquinamide.
Mephedrone Mephedrone may decrease the sedative activities of Benzquinamide.
Methoxyphenamine Methoxyphenamine may decrease the sedative activities of Benzquinamide.
Gepefrine Gepefrine may decrease the sedative activities of Benzquinamide.
2,5-Dimethoxy-4-ethylthioamphetamine 2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Benzquinamide.
Phendimetrazine Phendimetrazine may decrease the sedative activities of Benzquinamide.
Naltrexone The risk or severity of adverse effects can be increased when Benzquinamide is combined with Naltrexone.
Bezitramide The risk or severity of adverse effects can be increased when Benzquinamide is combined with Bezitramide.
Tramadol The risk or severity of adverse effects can be increased when Benzquinamide is combined with Tramadol.
Codeine The risk or severity of adverse effects can be increased when Benzquinamide is combined with Codeine.
Hydromorphone The risk or severity of adverse effects can be increased when Benzquinamide is combined with Hydromorphone.
Methadone The risk or severity of adverse effects can be increased when Benzquinamide is combined with Methadone.
Meperidine The risk or severity of adverse effects can be increased when Benzquinamide is combined with Meperidine.
Oxycodone The risk or severity of adverse effects can be increased when Benzquinamide is combined with Oxycodone.
Butorphanol The risk or severity of adverse effects can be increased when Benzquinamide is combined with Butorphanol.
Dextropropoxyphene The risk or severity of adverse effects can be increased when Benzquinamide is combined with Dextropropoxyphene.
Sufentanil The risk or severity of adverse effects can be increased when Benzquinamide is combined with Sufentanil.
Alfentanil The risk or severity of adverse effects can be increased when Benzquinamide is combined with Alfentanil.
Fentanyl The risk or severity of adverse effects can be increased when Benzquinamide is combined with Fentanyl.
Nalbuphine The risk or severity of adverse effects can be increased when Benzquinamide is combined with Nalbuphine.
Levorphanol The risk or severity of adverse effects can be increased when Benzquinamide is combined with Levorphanol.
Remifentanil The risk or severity of adverse effects can be increased when Benzquinamide is combined with Remifentanil.
Buprenorphine The risk or severity of adverse effects can be increased when Benzquinamide is combined with Buprenorphine.
Hydrocodone The risk or severity of adverse effects can be increased when Benzquinamide is combined with Hydrocodone.
Diphenoxylate The risk or severity of adverse effects can be increased when Benzquinamide is combined with Diphenoxylate.
Oxymorphone The risk or severity of adverse effects can be increased when Benzquinamide is combined with Oxymorphone.
Dezocine The risk or severity of adverse effects can be increased when Benzquinamide is combined with Dezocine.
Levacetylmethadol The risk or severity of adverse effects can be increased when Benzquinamide is combined with Levacetylmethadol.
Methadyl acetate The risk or severity of adverse effects can be increased when Benzquinamide is combined with Methadyl acetate.
Dihydroetorphine The risk or severity of adverse effects can be increased when Benzquinamide is combined with Dihydroetorphine.
Diamorphine The risk or severity of adverse effects can be increased when Benzquinamide is combined with Diamorphine.
Ethylmorphine The risk or severity of adverse effects can be increased when Benzquinamide is combined with Ethylmorphine.
Etorphine The risk or severity of adverse effects can be increased when Benzquinamide is combined with Etorphine.
Dextromoramide The risk or severity of adverse effects can be increased when Benzquinamide is combined with Dextromoramide.
Desomorphine The risk or severity of adverse effects can be increased when Benzquinamide is combined with Desomorphine.
Carfentanil The risk or severity of adverse effects can be increased when Benzquinamide is combined with Carfentanil.
Dihydrocodeine The risk or severity of adverse effects can be increased when Benzquinamide is combined with Dihydrocodeine.
Alphacetylmethadol The risk or severity of adverse effects can be increased when Benzquinamide is combined with Alphacetylmethadol.
Dihydromorphine The risk or severity of adverse effects can be increased when Benzquinamide is combined with Dihydromorphine.
Tapentadol The risk or severity of urinary retention and constipation can be increased when Benzquinamide is combined with Tapentadol.
Ketobemidone The risk or severity of adverse effects can be increased when Benzquinamide is combined with Ketobemidone.
DPDPE The risk or severity of adverse effects can be increased when Benzquinamide is combined with DPDPE.
Lofentanil The risk or severity of adverse effects can be increased when Benzquinamide is combined with Lofentanil.
Opium The risk or severity of adverse effects can be increased when Benzquinamide is combined with Opium.
Normethadone The risk or severity of adverse effects can be increased when Benzquinamide is combined with Normethadone.
Piritramide The risk or severity of adverse effects can be increased when Benzquinamide is combined with Piritramide.
Alphaprodine The risk or severity of adverse effects can be increased when Benzquinamide is combined with Alphaprodine.
Nicomorphine The risk or severity of adverse effects can be increased when Benzquinamide is combined with Nicomorphine.
Meptazinol The risk or severity of adverse effects can be increased when Benzquinamide is combined with Meptazinol.
Phenoperidine The risk or severity of adverse effects can be increased when Benzquinamide is combined with Phenoperidine.
Phenazocine The risk or severity of adverse effects can be increased when Benzquinamide is combined with Phenazocine.
Tilidine The risk or severity of adverse effects can be increased when Benzquinamide is combined with Tilidine.
Carfentanil, C-11 The risk or severity of adverse effects can be increased when Benzquinamide is combined with Carfentanil, C-11.
Morphine The risk or severity of adverse effects can be increased when Benzquinamide is combined with Morphine.
Pentazocine The risk or severity of adverse effects can be increased when Benzquinamide is combined with Pentazocine.
Benzhydrocodone The risk or severity of adverse effects can be increased when Benzquinamide is combined with Benzhydrocodone.
Naloxegol The risk or severity of adverse effects can be increased when Benzquinamide is combined with Naloxegol.
Trospium The risk or severity of adverse effects can be increased when Trospium is combined with Benzquinamide.
Oxyphenonium The risk or severity of adverse effects can be increased when Oxyphenonium is combined with Benzquinamide.
Benzatropine The risk or severity of adverse effects can be increased when Benzatropine is combined with Benzquinamide.
Disopyramide The risk or severity of adverse effects can be increased when Disopyramide is combined with Benzquinamide.
Metixene The risk or severity of adverse effects can be increased when Metixene is combined with Benzquinamide.

Target Protein

Histamine H1 receptor HRH1
Muscarinic acetylcholine receptor M4 CHRM4
Muscarinic acetylcholine receptor M1 CHRM1
Muscarinic acetylcholine receptor M5 CHRM5
Muscarinic acetylcholine receptor M2 CHRM2
Muscarinic acetylcholine receptor M3 CHRM3

Referensi & Sumber

Synthesis reference: Tretter, J.R.; US. Patent 3,053,845; September 11, 1962; assigned to Chas. Pfizer & Co., Inc. Lombardino, J.G. and McLamore, W.M.; U.S. Patent 3,055,894; September 25,1962; assigned to Chas. Pfizer & Co., Inc.

Contoh Produk & Brand

Produk: 0 • International brands: 5
International Brands
  • Benzchinamide
  • Emete-con — Pfizer
  • Emeticon — Pfizer
  • Promecon — Endo
  • Quantril — Pfizer

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul